130 related articles for article (PubMed ID: 19276288)
1. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.
Hochhauser D; Meyer T; Spanswick VJ; Wu J; Clingen PH; Loadman P; Cobb M; Gumbrell L; Begent RH; Hartley JA; Jodrell D
Clin Cancer Res; 2009 Mar; 15(6):2140-7. PubMed ID: 19276288
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
Puzanov I; Lee W; Chen AP; Calcutt MW; Hachey DL; Vermeulen WL; Spanswick VJ; Liao CY; Hartley JA; Berlin JD; Rothenberg ML
Clin Cancer Res; 2011 Jun; 17(11):3794-802. PubMed ID: 21346148
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
Janjigian YY; Lee W; Kris MG; Miller VA; Krug LM; Azzoli CG; Senturk E; Calcutt MW; Rizvi NA
Cancer Chemother Pharmacol; 2010 Apr; 65(5):833-8. PubMed ID: 19672598
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats.
Reid JM; Buhrow SA; Kuffel MJ; Jia L; Spanswick VJ; Hartley JA; Thurston DE; Tomaszewski JE; Ames MM
Cancer Chemother Pharmacol; 2011 Sep; 68(3):777-86. PubMed ID: 21188379
[TBL] [Abstract][Full Text] [Related]
5. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
6. γ-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: results from 2 phase I clinical trials of SJG-136 (SG2000).
Wu J; Clingen PH; Spanswick VJ; Mellinas-Gomez M; Meyer T; Puzanov I; Jodrell D; Hochhauser D; Hartley JA
Clin Cancer Res; 2013 Feb; 19(3):721-30. PubMed ID: 23251007
[TBL] [Abstract][Full Text] [Related]
7. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.
Wilkinson GP; Taylor JP; Shnyder S; Cooper P; Howard PW; Thurston DE; Jenkins TC; Loadman PM
Invest New Drugs; 2004 Aug; 22(3):231-40. PubMed ID: 15122070
[TBL] [Abstract][Full Text] [Related]
8. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
[TBL] [Abstract][Full Text] [Related]
9. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.
Wade Calcutt M; Lee W; Puzanov I; Rothenberg ML; Hachey DL
J Mass Spectrom; 2008 Jan; 43(1):42-52. PubMed ID: 17683023
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
Lockhart AC; Howard M; Hande KR; Roth BJ; Berlin JD; Vreeland F; Campbell A; Fontana E; Fiorentini F; Fowst C; Paty VA; Lankford O; Rothenberg ML
Clin Cancer Res; 2004 Jan; 10(2):468-75. PubMed ID: 14760067
[TBL] [Abstract][Full Text] [Related]
11. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours.
Mellinas-Gomez M; Spanswick VJ; Paredes-Moscosso SR; Robson M; Pedley RB; Thurston DE; Baines SJ; Stell A; Hartley JA
BMC Vet Res; 2015 Aug; 11():215. PubMed ID: 26282406
[TBL] [Abstract][Full Text] [Related]
12. LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).
Buhrow SA; Reid JM; Jia L; McGovern RM; Covey JM; Kobs DJ; Grossi IM; Ames MM
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Aug; 840(1):56-62. PubMed ID: 16730244
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
14. Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136.
Guichard SM; Macpherson JS; Thurston DE; Jodrell DI
Eur J Cancer; 2005 Aug; 41(12):1811-8. PubMed ID: 16046116
[TBL] [Abstract][Full Text] [Related]
15. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
16. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136.
Clingen PH; De Silva IU; McHugh PJ; Ghadessy FJ; Tilby MJ; Thurston DE; Hartley JA
Nucleic Acids Res; 2005; 33(10):3283-91. PubMed ID: 15944449
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Ten Tije AJ; Verweij J; Sparreboom A; Van Der Gaast A; Fowst C; Fiorentini F; Tursi J; Antonellini A; Mantel M; Hartman CM; Stoter G; Planting AS; De Jonge MJ
Clin Cancer Res; 2003 Aug; 9(8):2957-64. PubMed ID: 12912942
[TBL] [Abstract][Full Text] [Related]
18. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies.
Martin C; Ellis T; McGurk CJ; Jenkins TC; Hartley JA; Waring MJ; Thurston DE
Biochemistry; 2005 Mar; 44(11):4135-47. PubMed ID: 15766241
[TBL] [Abstract][Full Text] [Related]
19. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
